Seeking Alpha

BioMimetic Therapeutics (BMTI) soars 16.1% after submitting more information to the FDA about...

BioMimetic Therapeutics (BMTI) soars 16.1% after submitting more information to the FDA about its Augment treatment, saying that the bone-graft product is not inferior to autograft. The agency decided not to OK Augment in January, when it asked for the additional data. BioMimetic now expects a decision on approval next year or in early 2014. (PR)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector